Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Chess Study Revives Debate Over Cognition-Enhancing Drugs
JAMA doi:10.1001/JAMA:2017.8114, Lyon, J., 2017
Non-Alzheimers Dementia 3 Vascular Dementia
Lancet 386:1698-1706, OBrien, J.T. & Thomas, A., 2015
Responding to Requests from Adult Patients for Neuroenhancements
Neurol 73:1406-1412, Larriviere,D.,et al, 2009
Safety and Efficacy of Galantamine in Subjects with Mild Cognitive Impairment
Neurol 70:2024-2035, Winblad,B.,et al, 2008
Transient Global Amnesia: Increasing Evidence of a Venous Etiology
Arch Neurol 63:1334-1336 ,1336, Menendez,M. &Rivera,M.M., 2006
Potassium Channel Antibody-Associated Encephalopathy: A Potentially Immunotherapy-Responsive Form of Limbic Encepahlitis
Brain 127:701-712, Vincent,A.,et al, 2004
Effect of Radiotherapy and Other Treatment-Related Factors on Mid-Term to Long-Term Cognitive Sequelae in Low-Grade Gliomas: A Comparative Study
Lancet 360:1361-1368, Klein,M.,et al, 2002